Chemotherapeutic Approaches for Targeting Cell Death Pathways

CME Activity Information
Release Date:	April 13, 2006
Most Recent Review:	May 15, 2007*
Most Recent Update:	April 13, 2006
Date Credit Expires:	April 13, 2008
Time to Complete:	1 hour
Medium:	Internet Online
*Click here to learn more about our review process.

Instructions for Participation

1. Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
2. Study the educational activity
3. Complete the CME quiz and evaluation
4. After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

   *The CME quiz and evaluation must be completed by April 13, 2008, in order to receive the credit or participation certificate.

1. List the multiple cell death pathways that are activated in response to chemotherapeutic agents.
2. Identify signaling molecules involved and morphological changes that occur in the different types of cell death pathways.
3. Describe mechanisms targeted by novel chemotherapeutic agents.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process: http://theoncologist.alphamedpress.org/misc/ifora.shtml. All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Credentials: National Cancer Institute and Food and Drug Administration Interagency Oncology Task Force, Bethesda, Maryland, USA.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of the following products, devices or techniques for cancer treatment: Genta/Aventis's UOblimersen (Genasense), Harvard University's SAHBs, Abbott's ABT-737 and A-641397, NCI/Ascenta's gossypol, University of Texas Southwestern's Compound 3, Aegera/Hybridon's AEG 35156/GEM640, The Burnham Institute's Polyphenylureas, Hoffman-La Roche's Nutlins, Genentech/Amgen's TRAIL, Human Genome Sciences's HGS-ETR2, Dartmouth College/Reata's CDDO, Cytokinetics/GlaxoSmithKline's SB-715992, National Cancer Institute's (NCI) UCN-01, Cephalon's CEP-3891, GlaxoSmithKline's SB-218078, Wyeth/NCI/others CCI-779 (temsirolimus), Ariad's AP23573, Novartis's RAD001, NCI's (and multiple sponsors) Sirolimus.

Wei-Xing Zong, Ph.D.

Credentials: Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, New York, USA. Telephone: 631-632-4104; Fax: 631-632-9797; E-mail: wzong{at}notes.cc.sunysb.edu.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of the following for cancer treatment: Genta/Aventis's UOblimersen (Genasense), Harvard University's SAHBs, Abbott's ABT-737 and A-641397, NCI/Ascenta's gossypol, University of Texas Southwestern's Compound 3, Aegera/Hybridon's AEG 35156/GEM640, The Burnham Institute's Polyphenylureas, Hoffman-La Roche's Nutlins, Genentech/Amgen's TRAIL, Human Genome Sciences's HGS-ETR2, Dartmouth College/Reata's CDDO, Cytokinetics/GlaxoSmithKline's SB-715992, National Cancer Institute's (NCI) UCN-01, Cephalon's CEP-3891, GlaxoSmithKline's SB-218078, Wyeth/NCI/others CCI-779 (temsirolimus), Ariad's AP23573, Novartis's RAD001, NCI's (and multiple sponsors) Sirolimus.